Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIOLARGO, INC.

Get SEC filing alerts via email and in your feed for BIOLARGO, INC.

BLGO

BIOLARGO, INC.

About BIOLARGO, INC.

BioLargo, Inc. develops and commercializes innovative cleantech solutions addressing environmental and health challenges. Its core businesses include industrial and consumer odor and VOC control products, advanced water treatment systems targeting contaminants like PFAS and micropollutants, long-duration battery energy storage technologies, and antimicrobial medical devices. Operating through specialized subsidiaries, BioLargo serves municipal, industrial, and healthcare markets by delivering patented, energy-efficient, and environmentally sustainable technologies supported by engineering services.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BIOLARGO, INC.

1
1
BIOLARGO, INC. BioLargo Reports 66% Revenue Decline and $3.405 Million Net Loss in Q1 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
BIOLARGO, INC. BioLargo Reports 56% Revenue Decline and $15.19 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
BIOLARGO, INC. BioLargo Reports 75% Revenue Decline and $7.2 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BIOLARGO, INC. BioLargo Reports 45% Revenue Decline and Increased Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BIOLARGO, INC. BioLargo Reports 31% Revenue Decline in Q1 2025, Operating Loss Increases

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BIOLARGO, INC. BioLargo Reports 45% Revenue Growth to $17.8 Million, Despite Net Loss of $4.35 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BIOLARGO, INC. BioLargo Reports 63% Revenue Growth, Narrowed Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments